Breaking News

Lonza, Benitec Enter AVV Mfg. Services Agreement

To develop scalable manufacturing process for ddRNAi therapeutics

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Lonza Houston, Inc., a global provider of biological, cell and viral gene therapy manufacturing, and Benitec Biopharma, biopharma company commercializing a gene-silencing technology, DNA-directed RNA interference (ddRNAi), have entered into a manufacturing services agreement to develop a scalable manufacturing process for Benitec’s ddRNAi-based, Adeno-Associated Virus (AAV)-delivered products intended for therapeutic use in humans.   Lonza will work develop a cost-effective, scalable and...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters